Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020	[1],[2]
Deferred tax assets:
Net operating loss carryforwards	$ 53.0		$ 46.4	$ 53.0
Capitalized research and development expenses	49.3		211.9	49.3
Tax credits	105.5		61.1	105.5
Share-based compensation	13.3		16.8	13.3
Fixed and intangible assets	26.4		34.4	26.4
Accrued liabilities and reserves	105.5		105.3	105.5
Collaborative agreement milestone accrual	21.9		0.0	21.9
Convertible debt	21.6		9.3	21.6
Other	0.5		0.0	0.5
Total gross deferred tax assets	397.0		485.2	397.0
Less: valuation allowance	(69.9)		(78.7)	(69.9)
Total net deferred tax assets	327.1		406.5	327.1
Deferred tax liabilities:
Fixed assets and acquired intangibles assets	(42.5)		(69.9)	(42.5)
Other	0.0		(0.3)	0.0
Total deferred tax liabilities	(42.5)		(70.2)	(42.5)
Net deferred tax assets (liabilities)	284.6		336.3	284.6
Collaborative research and development fee			$ 0.0	$ 87.1	[1],[2]	$ 0.0
Collaborative Arrangement, Initial Payment | Verily Life Sciences | Collaborative Arrangement
Deferred tax liabilities:
Collaborative research and development fee	$ 87.1	$ 217.7

[1] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.

[2] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.